A Comparison of TNF-α Expression by Cyanidin-3-O-Lathyroside and Dexamethasone: A Proposed Study
Event Type
Research Presentation
Location
Dana Science Building, 2nd floor
Start Date
24-4-2026 1:00 PM
End Date
24-4-2026 2:30 PM
Description
Both during and after cancer treatment, chronic inflammation becomes an issue due to systemic TNF-α production. When a suppressant is given to a patient to combat these issues, the entire NF-kB response is shut down, leading to a lack of an immune system response. This research proposal puts forward a modification of a recent study on Cyanidin-3-O-lathyroside to see whether or not this substance can improve chronic inflammation treatments, specifically in cancer patients. This study will utilize an in vitro macrophage model using RAW 264.7 cells found in mice. The cells will be induced with Lipopolysaccharide and injected with Cyanidin-3-O-lathyroside. Changes in cytokine levels will be monitored post injection. With this research proposal, finding a minimum effective concentration of Cyanidin-3-O-lathyroside can help optimize doses that are essential to drug development. By studying this compound, we hope to have a better understanding of how these compounds can impact pharmacological research, and enhance drug discovery efforts in treatment of chronic inflammation.
A Comparison of TNF-α Expression by Cyanidin-3-O-Lathyroside and Dexamethasone: A Proposed Study
Dana Science Building, 2nd floor
Both during and after cancer treatment, chronic inflammation becomes an issue due to systemic TNF-α production. When a suppressant is given to a patient to combat these issues, the entire NF-kB response is shut down, leading to a lack of an immune system response. This research proposal puts forward a modification of a recent study on Cyanidin-3-O-lathyroside to see whether or not this substance can improve chronic inflammation treatments, specifically in cancer patients. This study will utilize an in vitro macrophage model using RAW 264.7 cells found in mice. The cells will be induced with Lipopolysaccharide and injected with Cyanidin-3-O-lathyroside. Changes in cytokine levels will be monitored post injection. With this research proposal, finding a minimum effective concentration of Cyanidin-3-O-lathyroside can help optimize doses that are essential to drug development. By studying this compound, we hope to have a better understanding of how these compounds can impact pharmacological research, and enhance drug discovery efforts in treatment of chronic inflammation.
Comments
Under the direction of Dr. Mary Jane Carmichael and Dr. Daniel Derringer.